DJIA 18,132.70 -81.72 -0.45%
NASDAQ 4,963.53 -24.36 -0.49%
S&P 500 2,104.50 -6.24 -0.30%
market minute promo

Alkermes, Inc. (NASDAQ: ALKS)

70.25 -0.98 (-1.38%)

REAL-TIME: Last trade at

Extended Hours: $70.26 $0.01 (0.01%)
Quote as of (NASDAQ)



company name or ticker

Recent Quotes

ALKS $70.25 -1.38%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $71.68
Previous Close $71.23
Daily Range $69.81 - $72.10
52-Week Range $38.49 - $74.96
Market Cap $10.4B
P/E Ratio -339.19
Dividend (Yield) $0.00 (0.0%)
Volume 6,215,947
Average Daily Volume 1,316,131
Current FY EPS -$0.19

Sector

Healthcare

Industry

Drug Makers

Alkermes, Inc. (ALKS) Description

A biotechnology company that develops innovative medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious disease. Website: http://www.alkermes.com/

News & Commentary

This Could Be Game-Changing News in the Battle Against Multiple Sclerosis

Multiple sclerosis affects more than 400,000 people in the United States and around 2.5 million people globally. That's why this potentially game-changing study's results are so promising and important.

Biotech Stock Roundup: Pharmacyclics Up on Buyout Rumors, Celgene Drug Label Expanded - Analyst B

Biotech Stock Roundup: Pharmacyclics Up on Buyout Rumors, Celgene Drug Label Expanded - Analyst Blog

How To Beat The Herd Mentality: Highline's Michael Higgins

Alkermes Falls on Pipeline News; Q4 Earnings Plunge Y/Y - Analyst Blog

Alkermes Falls on Pipeline News; Q4 Earnings Plunge Y/Y - Analyst Blog

Alkermes' (ALKS) CEO Rich Pops on Q4 2014 Results - Earnings Call Transcript

Jim Cramer: Use Share Weakness to Buy Alkermes for Its Drug Pipeline

Alkermes (ALKS) Q3 2015 Results - Earnings Call Webcast

Next Week In Biotech: Arena And Vivus Report, Radiesse And Avedro Ad Comms

Biotech Stock Roundup: Achillion Impresses with HCV Data, Regeneron 4Q Results Top Estimates - Analy

Biotech Stock Roundup: Achillion Impresses with HCV Data, Regeneron 4Q Results Top Estimates - Analyst Blog

Jim Cramer's Top Stock Picks: GM HAS SAVE ALKS

Alkermes Reports Positive Data on Multiple Sclerosis Drug - Analyst Blog

See More ALKS News...

ALKS's Top Competitors

ALKS $70.25 (-1.38%)
Current stock: ALKS
AMGN $157.72 (-0.79%)
Current stock: AMGN
GILD $103.53 (-0.63%)
Current stock: GILD
BIIB $409.59 (-0.12%)
Current stock: BIIB